505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Announces Reverse Stock Split
Annual Meeting Results: Election of Class III Directors Confirmed
Annual Report to Security Holders
Artelo Biosciences Enters At The Market Offering Agreement for $6.53M
Termination of At-The-Market Offering Agreement with R.F. Lafferty
Regains Compliance with Nasdaq Listing Requirements
Announces Closing of $11.0 Million Private Placement
Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Amended Quarterly Report
Q2
Q1
FY 2024
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Additional Proxy Materials
PRER14A
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence